Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Fassan, Matteo ^a,b   D'Arca, Domenico ^a   Letko, Juraj ^a   Vecchione, Andrea ^a,c   Gardiman, Marina P ^b   McCue, Peter ^a   Wildemore, Bernadette ^a   Rugge, Massimo ^b   Shupp Byrne, Dolores ^a   Gomella, Leonard G ^a   Morrione, Andrea ^a   Iozzo, Renato V ^a   Baffa, Raffaele ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Sanofi Aventis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMININ; SMALL INTERFERING RNA; MITOSTATIN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSTATIN GENE; MOUSE; NONHUMAN; PHENOTYPE; PROSTATE CANCER; TUMOR SUPPRESSOR GENE; ANIMAL; CANCER INVASION; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; PROSTATIC NEOPLASMS; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 79955812386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019771     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 59: 225-249.
2. Vecchione A, Gottardo F, Gomella LG, Wildemore B, Fassan M, et al. (2007) Molecular genetics of prostate cancer: clinical translational opportunities. J Exp Clin Cancer Res 26: 25-37.
3. Field JK, Kiaris H, Risk JM, Tsiriyotis C, Adamson R, et al. (1995) Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. Br J Cancer 72: 1180-1188.
4. Shiseki M, Kohno T, Adachi J, Okazaki T, Otsuka T, et al. (1996) Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosomes Cancer 17: 71-77.
5. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, et al. (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57: 1222-1227.
6. Schmutte C, Baffa R, Veronese LM, Murakumo Y, Fishel R, (1997) Human thymine-DNA glycosylase maps at chromosome 12q22-q24.1: a region of high loss of heterozygosity in gastric cancer. Cancer Res 57: 3010-3015.
7. Kimura M, Furukawa T, Abe T, Yatsuoka T, Youssef EM, et al. (1998) Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer. Cancer Res 58: 2456-2460.
8. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, et al. (1998) Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 153: 1467-1473.
9. Koo SH, Kwon KC, Ihm CH, Jeon YM, Park JW, et al. (1999) Detection of genetic alterations in bladder tumors by comparative genomic hybridization and cytogenetic analysis. Cancer Genet Cytogenet 110: 87-93.
10. Rijken AM, Hu J, Perlman EJ, Morsberger LA, Long P, et al. (1999) Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer 26: 185-191.
11. Aubele MM, Cummings MC, Mattis AE, Zitzelsberger HF, Walch AK, et al. (2000) Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol 9: 14-19.
12. Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B, (1999) Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 39: 79-86.
13. Vecchione A, Fassan M, Anesti V, Morrione A, Goldoni S, et al. (2009) MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer. Oncogene 28: 257-269.
14. Kim YR, Kim SS, Yoo NJ, Lee SH, (2010) Mutational Analysis of MITOSTATIN, a candidate tumor-suppressor gene, at a mononucleotide repeat in gastric and colorectal carcinoma. Gut and Liver 4: 149-150.
15. Cerqua C, Anesti V, Pyakurel A, Liu D, Naon D, et al. (2010) Trichoplein/Mitostatin regulates endoplasmic reticulum-mitochondria juxtaposition. EMBO Rep 11: 854-860.
16. Merle B, Durussel L, Delmas PD, Clezardin P, (1999) Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 75: 538-546.
17. Kinsella MG, Fischer JW, Mason DP, Wight TN, (2000) Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem 275: 13924-13932.
18. Xu G, Guimond MJ, Chakraborty C, Lala PK, (2002) Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod 67: 681-689.
19. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, et al. (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21: 4765-4777.
20. Parcellier A, Schmitt E, Gurbuxani S, Seigneurin-Berny D, Pance A, et al. (2003) HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol 23: 5790-5802.
21. Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, et al. (2009) Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol 174: 1037-1047.
22. Rabinovitz I, Cress AE, Nagle RB, (1994) Biosyntesis and secretion of laminin and S-laminin by human prostate carcinoma cell lines. Prostate 25: 97-107.
23. Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, et al. (2001) Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 12: 99-107.
24. Goldoni S, Iozzo RV, (2008) Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123: 2473-2479.
25. Danielson KG, Fazzio A, Cohen I, Cannizzaro LA, Eichstetter I, et al. (1993) The human decorin gene: intron-exon organization, discovery of two alternatively spliced exons in the 5′ untranslated region, and mapping of the gene to chromosome 12q23. Genomics 15: 146-160.
26. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV, (1995) De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A 92: 7016-7020.
27. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, et al. (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100: 149-157.
28. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, et al. (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101: 406-412.
29. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, et al. (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275: 32879-32887.
30. Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K, (2001) Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). J Biol Chem 276: 40687-40692.
31. Xaus J, Comalada M, Cardo M, Valledor AF, Celada A, (2001) Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1). Blood 98: 2124-2133.
32. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, et al. (2007) A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26: 368-381.
33. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, et al. (2008) An antimetastatic role for decorin in breast cancer. Am J Pathol 173: 844-855.
34. Ferdous Z, Peterson SB, Tseng H, Anderson DK, Iozzo RV, et al. (2010) A role for decorin in controlling proliferation, adhesion, and migration of murine embryonic fibroblasts. J Biomed Mater Res A 93: 419-428.
35. Reed CC, Gauldie J, Iozzo RV, (2002) Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21: 3688-3695.
36. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, et al. (2006) Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281: 26408-26418.
37. Tralhao JG, Schaefer L, Micegova M, Evaristo C, Schonherr E, et al. (2003) In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. Faseb J 17: 464-466.
38. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, et al. (1998) Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 1614-1617.
39. Tamura M, Gu J, Takino T, Yamada KM, (1999) Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59: 442-449.
40. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, et al. (2001) Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 61: 6945-6951.
41. Romano G, Reiss K, Tu X, Peruzzi F, Belletti B, et al. (2001) Efficient in vitro and in vivo gene regulation of a retrovirally delivered pro-apoptotic factor under the control of the Drosophila HSP70 promoter. Gene Ther 8: 600-607.
42. Monami G, Gonzalez EM, Hellman M, Gomella LG, Baffa R, et al. (2006) Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 66: 7103-7110.
43. Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, et al. (2009) Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis 30: 861-868.
44. Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, et al. (2002) FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 160: 1345-1352.